Vanguard Group’s Eterna Therapeutics ERNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $43.1K | Buy |
1,437
+991
| +222% | +$33.7K | ﹤0.01% | 4259 |
|
|
2025
Q3 | $12.2K | Buy |
+446
| New | +$17.7K | ﹤0.01% | 4336 |
|
|
2025
Q2 | – | Sell |
-102
| Closed | -$6.8K | – | 4292 |
|
|
2025
Q1 | $6.8K | Buy |
102
+32
| +46% | +$3.95K | ﹤0.01% | 4265 |
|
|
2024
Q4 | $7.67K | Hold |
70
| – | – | ﹤0.01% | 4285 |
|
|
2024
Q3 | $27.4K | Hold |
70
| – | – | ﹤0.01% | 4282 |
|
|
2024
Q2 | $47.8K | Hold |
70
| – | – | ﹤0.01% | 4295 |
|
|
2024
Q1 | $62.6K | Hold |
70
| – | – | ﹤0.01% | 4289 |
|
|
2023
Q4 | $46.8K | Buy |
70
+4
| +6% | +$2.29K | ﹤0.01% | 4378 |
|
|
2023
Q3 | $54.3K | Buy |
66
+15
| +29% | +$13.8K | ﹤0.01% | 4405 |
|
|
2023
Q2 | $43.1K | Hold |
51
| – | – | ﹤0.01% | 4473 |
|
|
2023
Q1 | $64.8K | Sell |
51
-27
| -35% | -$40.6K | ﹤0.01% | 4445 |
|
|
2022
Q4 | $93.6K | Sell |
78
-40
| -34% | -$56.4K | ﹤0.01% | 4401 |
|
|
2022
Q3 | $220K | Sell |
118
-34
| -22% | -$117K | ﹤0.01% | 4399 |
|
|
2022
Q2 | $590K | Sell |
152
-20
| -12% | -$144K | ﹤0.01% | 4246 |
|
|
2022
Q1 | $2.64M | Sell |
172
-3
| -2% | -$56.9K | ﹤0.01% | 3840 |
|
|
2021
Q4 | $5.46M | Buy |
175
+102
| +140% | +$5.55M | ﹤0.01% | 3557 |
|
|
2021
Q3 | $5.06M | Buy |
73
+18
| +33% | +$1.55M | ﹤0.01% | 3655 |
|
|
2021
Q2 | $7.37M | Buy |
+55
| New | +$7.92M | ﹤0.01% | 3374 |
|
|
2021
Q1 | – | Sell |
-1
| Closed | -$36K | – | 4335 |
|
|
2020
Q4 | $36K | Hold |
1
| – | – | ﹤0.01% | 4190 |
|
|
2020
Q3 | $28K | Hold |
1
| – | – | ﹤0.01% | 4086 |
|
|
2020
Q2 | $36K | Hold |
1
| – | – | ﹤0.01% | 4041 |
|
|
2020
Q1 | $25K | Hold |
1
| – | – | ﹤0.01% | 4036 |
|
|
2019
Q4 | $36K | Hold |
1
| – | – | ﹤0.01% | 4060 |
|
|
2019
Q3 | $55K | Hold |
1
| – | – | ﹤0.01% | 4077 |
|
|
2019
Q2 | $62K | Hold |
1
| – | – | ﹤0.01% | 4087 |
|
|
2019
Q1 | $65K | Hold |
1
| – | – | ﹤0.01% | 4044 |
|
|
2018
Q4 | $32K | Hold |
1
| – | – | ﹤0.01% | 4100 |
|
|
2018
Q3 | $95K | Hold |
1
| – | – | ﹤0.01% | 4081 |
|
|
2018
Q2 | $94K | Hold |
1
| – | – | ﹤0.01% | 4056 |
|
|
2018
Q1 | $144K | Hold |
1
| – | – | ﹤0.01% | 3995 |
|
|
2017
Q4 | $71K | Hold |
1
| – | – | ﹤0.01% | 4020 |
|
|
2017
Q3 | $108K | Hold |
1
| – | – | ﹤0.01% | 3981 |
|
|
2017
Q2 | $120K | Hold |
1
| – | – | ﹤0.01% | 3975 |
|
|
2017
Q1 | $120K | Hold |
1
| – | – | ﹤0.01% | 3974 |
|
|
2016
Q4 | $115K | Hold |
1
| – | – | ﹤0.01% | 3965 |
|
|
2016
Q3 | $92K | Hold |
1
| – | – | ﹤0.01% | 3986 |
|
|
2016
Q2 | $143K | Hold |
1
| – | – | ﹤0.01% | 3985 |
|
|
2016
Q1 | $99K | Hold |
1
| – | – | ﹤0.01% | 4028 |
|
|
2015
Q4 | $106K | Hold |
1
| – | – | ﹤0.01% | 4074 |
|
|
2015
Q3 | $210K | Hold |
1
| – | – | ﹤0.01% | 4024 |
|
|
2015
Q2 | $152K | Hold |
1
| – | – | ﹤0.01% | 4081 |
|
|
2015
Q1 | $273K | Hold |
1
| – | – | ﹤0.01% | 3948 |
|
|
2014
Q4 | $282K | Hold |
1
| – | – | ﹤0.01% | 3845 |
|
|
2014
Q3 | $206K | Hold |
1
| – | – | ﹤0.01% | 3887 |
|
|
2014
Q2 | $331K | Buy |
+1
| New | +$440K | ﹤0.01% | 3770 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3793 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 3746 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 3766 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 3712 |
|
Other funds holding ERNA
HF
SCA
FFO
Vanguard Group's ERNA Position: Q4 2025 in Review
Vanguard Group increased its Eterna Therapeutics (ERNA) stake by 222% in Q4 2025, buying an estimated $33.7K and bringing the position to 1,437 shares worth $43.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4259.
Vanguard Group first reported a position in ERNA in Q2 2014 and has held it in 45 quarters since. The position peaked at $7.37M in Q2 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2025.
- Vanguard Group held 1,437 shares of Eterna Therapeutics worth $43.1K as of Q4 2025.
- Vanguard Group bought 991 Eterna Therapeutics shares in Q4 2025, an estimated $33.7K.
- Eterna Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4259 holding.
- Vanguard Group first reported a position in Eterna Therapeutics in Q2 2014 and has held it in 45 quarters since.
- Vanguard Group's Eterna Therapeutics position peaked at $7.37M in Q2 2021.
- 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.